Background: The Optilume benign prostatic hyperplasia (BPH) catheter system is a novel minimally invasive paclitaxel-coated dilation system that has demonstrated substantial and durable results in urinary flow and symptoms.
Aim: We now assess the impact of Optilume BPH procedure on sexual function.
Methods: Prior published results have described the methods of data collection during the PINNACLE study, which demonstrated durable improvement in urinary symptoms. Follow-up assessments for the current study included IIEF-EF and Male Sexual Health Questionnaire for Ejaculatory Dysfunction (MSHQ-EjD). Semen quality was also examined.
Outcomes: IIEF-EF and MSHQ-EjD scores in the Optilume BPH group were not different from the sham group at 3 months, 6 months, or 12 months.
Results: A total of 148 men were randomized to receive the procedure (100) or a sham surgical procedure (48). Subjects in both groups had similar rates of erectile dysfunction (ED) previously diagnosed at baseline (56% vs 54.2%, P = .83) and those men who were sexually active. IIEF-EF and MSHQ-EjD scores in the Optilume BPH group were not different from the sham group at 3, 6, or 12 months. Change in IIEF-EF scores remained consistent across all levels of baseline ED severity after Optilume BPH procedure. No clear trend was seen after treatment with Optilume BPH for semen volume, sperm motility, progressive motility, or sperm morphology.
Clinical Implications: The Optilume BPH catheter system provides patients with a durable improvement in lower urinary tract symptoms while preserving sexual function.
Strengths And Limitations: This study uses validated questionnaires to assess patients' sexual function at baseline and regularly for 1 year after the procedure. Given exclusion criteria regarding patient age and prostate size, the results may not be applicable to all BPH phenotypes.
Conclusion: Optilume appears to provide clinical benefit with a high degree of patient satisfaction and minimal impact on sexual function.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jsxmed/qdae206 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preservation of sexual function with Optilume-a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia.
J Sex Med
January 2025
The Center for Men's Health Stritch School of Medicine, Maywood, IL 60153, United States.
Background: The Optilume benign prostatic hyperplasia (BPH) catheter system is a novel minimally invasive paclitaxel-coated dilation system that has demonstrated substantial and durable results in urinary flow and symptoms.
Aim: We now assess the impact of Optilume BPH procedure on sexual function.
Methods: Prior published results have described the methods of data collection during the PINNACLE study, which demonstrated durable improvement in urinary symptoms.
Recent Advancements in Prostate Catheters and Stents for Management of Benign Prostatic Hyperplasia.
Curr Urol Rep
October 2024
Department of Urology, Northwell Health, Manhasset, NY, USA.
Purpose Of Review: The prevalence of benign prostatic hyperplasia (BPH) is rising, however, current treatment options present severe complications and limit patient's quality of life. Accordingly, advancements in prostatic catheter and stent designs for use in treating lower urinary tract symptoms (LUTS) in BPH patients have largely expanded in the past five years and we aim to provide an exhaustive summary of recent outcomes.
Recent Findings: The dual dilation and paxlitaxel eluting Optilume BPH Catheter System enhances promise in catheter-based treatments, providing the longest sustained increase in max urinary flow rate and decrease in post-void residual volume compared to alternative MISTs.
Absence of Race/Ethnicity Reporting in Clinical Trials of True Minimally Invasive Surgical Therapies for the Treatment of Benign Prostatic Hyperplasia.
Urology
October 2024
Division of Urology, Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montreal, QC, Canada. Electronic address:
Objective: To assess the extent of racial reporting and enrollment in randomized controlled trials (RCTs) of minimally invasive surgical therapies (MIST) for the office-based treatment of benign prostatic hyperplasia (BPH).
Methods: A systematic review was conducted for RCTs assessing 6 office-based MISTs: transurethral microwave thermotherapy (TUMT), prostatic artery embolization, prostatic urethral lift, temporary implantable nitinol device, water vapor thermal therapy, and Optilume. MEDLINE, Embase, and the Cochrane CENTRAL databases were searched up to November 3, 2023.
Advances in Outpatient Therapies and Treatment of Benign Prostatic Hyperplasia: A Comprehensive Review for Men's Health.
Med Clin North Am
September 2024
Division of Urology, Department of Surgery, Emory University, 1365 Clifton Road NorthEast, Building B 1st Floor, Suite 1400, Atlanta, GA 30322, USA.
Article Synopsis
- Benign prostate hyperplasia (BPH) is common among men and can be managed through various methods: behavioral changes, medications, and surgery.
- Recently, β3-agonists have been introduced for treating overactive urinary tract symptoms, enhancing medical therapy options.
- There has been a surge in minimally invasive and surgical treatment options over the last decade, allowing healthcare providers to customize BPH treatments based on individual patient needs and disease specifics.
The Optilume BPH Catheter System for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Transl Androl Urol
June 2024
Department of Biochemistry and Molecular Biology, Augusta University, Augusta, GA, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!